Abdul Siddiqui, MD
Pulmonary Disease · London, KYNPI 1912331323
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (53.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 66.7% of it on its own, with 38 other manufacturers making up the rest. 2025 is the largest year on record at $10,267, more than ten times the $567 reported in 2019.
Across 244 payments — averaging $65.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$11K
- GSK$1K
- AstraZeneca$994
- Boehringer Ingelheim$527
- Grifols USA, LLC$390
- Sanofi$220
- plus $2K from 33 others
What the payments were for
- Travel & lodging$1,99813%
- Food & beverage$5,35634%
- Education$8,56254%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 16 | $10,623 |
| GSK | 50 | $1,008 |
| AstraZeneca | 30 | $994 |
| Boehringer Ingelheim | 24 | $527 |
| Grifols USA, LLC | 12 | $390 |
| Sanofi | 12 | $220 |
| Amgen | 4 | $181 |
| Insmed, Inc. | 9 | $169 |
| Vanda Pharmaceuticals Inc. | 6 | $158 |
| Mylan Specialty L.p. | 8 | $152 |
| Regeneron Healthcare Solutions, Inc. | 8 | $149 |
| Biohaven Pharmaceuticals, Inc. | 1 | $125 |
| Amarin Pharma, Inc. | 1 | $124 |
| Pfizer | 7 | $123 |
| Bayer | 5 | $90 |
| Axsome Therapeutics, Inc. | 4 | $85 |
| Genentech USA, Inc. | 5 | $79 |
| Electromed, Inc. | 6 | $76 |
| Harmony Biosciences LLC | 2 | $65 |
| Jazz Pharmaceuticals Inc. | 4 | $64 |
| Actelion Pharmaceuticals US, Inc. | 4 | $57 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Merck | 3 | $49 |
| Circassia Inc. | 2 | $38 |
| Philips North America LLC | 2 | $35 |
| Phadia US Inc. | 2 | $30 |
| Pulmonx Corporation | 1 | $26 |
| AbbVie | 1 | $25 |
| Verona Pharma, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| CSL Behring | 1 | $22 |
| Viatris Specialty LLC | 1 | $21 |
| Nabriva Therapeutics, PLC | 1 | $20 |
| Baxter Healthcare | 1 | $20 |
| Novo Nordisk | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 2 | $15 |
| Advanced Respiratory, Inc | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| Resmed Corp | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$10,493
- TEZSPIRE$372
- NURTEC ODT$125
- Prolastin-C Liquid$125
- NUCALA$125
- AIRSUPRA$125
- Vascepa$124
- TRELEGY ELLIPTA$113
How this compares
$15,916 in reported general payments places this provider in the 85th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 122 | $84,356 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 110 | $71,409 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 83 | $43,035 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 49 | $27,000 |
| Spiriva RespimatTiotropium Bromide | 34 | $21,421 |
| EliquisApixaban | 14 | $17,046 |
| Spiriva HandihalerTiotropium Bromide | 21 | $11,613 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 72 | $9,877 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $5,779 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $5,504 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $5,448 |
| BreynaBudesonide/Formoterol Fumarate | 15 | $2,424 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 62 | $2,076 |
| Roflumilast | 24 | $1,728 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,631 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,008 | $103,858173 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $994 | $90,135149 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $527 | $64,456117 claims |
| PfizerEliquis | $123 | $17,04614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in London
- Aqeel MandviwalaLondon$11K
- John McConnellLouisville$864K
- Erica GregonisRichmond$390K
- Firas KouraGeorgetown$350K
- Harold HallerLouisville$340K
- Steven KoenigMorehead$242K
- Samantha BaahLouisville$226K
- Sandra SchuldheiszSomerset$225K
- Karim El-KershLouisville$180K
- Dennis DohertyLexington$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.